In the News
Accelerating Alzheimer’s Research: Groundbreaking Alzheimer’s Disease Dataset Now Available to the Public
Data from Most Deeply Characterized Cohort Across Alzheimer’s Disease Released byGlobal Alzheimer’s Platform Foundation and Alzheimer’s Disease Data Initiative Washington D.C., July 31, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) and the Alzheimer’s Disease Data Initiative (AD Data Initiative) announced today that data generated from the Bio-Hermes-001 study are now publicly available. This release […]
AInvest: Roche’s Alzheimer’s Prevention Gambit: A Game-Changer in a $13B Market?
OliverBlake, Sunday, Jul 27, 2025 4:21 pm ETThe global Alzheimer’s disease market is a high-stakes arena where innovation and precision collide. With over 60 million people affected worldwide and a projected $19.44 billion market size by 2030, the race to develop disease-modifying therapies (DMTs) and diagnostics is intensifying. Roche, a pharmaceutical giant with a legacy […]
Global Alzheimer’s Platform Foundation and Genentech Collaborate to Expand Access to Alzheimer’s Research
Washington, DC -July 28, 2025 –The Global Alzheimer’s Platform Foundation® (GAP), an international leader in accelerating clinical trials and improving recruitment, announced a collaboration with Genentech, a member of the Roche Group, to expand access to clinical trials for communities underrepresented in Alzheimer’s research. This partnership will leverage the combined expertise of GAP’s Site Alliance […]
GAP Experts to Present at Prestigious International Conference
Showcase on Bio-Hermes Data Challenge and Poster Presentation to Take Place at the Alzheimer’s Association International Conference (AAIC) Washington D.C., July 23, 2025- The Global Alzheimer’s Platform Foundation® , (GAP) will have a poster presentation and a Featured Research Session at the 2025 Alzheimer’s Association International Conference (AAIC) being held in Toronto, Canada. Poster Presentation […]
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with IXICO for the Transformative Bio-Hermes-002 Study
IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias Washington D.C., July 22, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome IXICO, a global leader in neuroscience imaging and biomarker analytics, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study […]
BioSpace: Alzheimer’s Disease Diagnostics Market Size to Reach USD 25.53 Billion by 2034
June 30, 2025 | 1 min read The global alzheimer’s disease diagnostics market size is calculated at USD 8.95 billion in 2024, grows to USD 9.94 billion in 2025, and is projected to reach around USD 25.53 billion by 2034, growing at a CAGR of 11.05% from 2025 to 2034. Rising regulatory approvals, innovative product launches, research funding […]
WPRI: Bridging the gap: How Progreso Latino is changing the face of Alzheimer’s research
by: Alex Torres-Perez, Posted: Jun 30, 2025 CENTRAL FALLS, R.I. (WPRI) — Central Falls-based Progreso Latino has been awarded the Global Alzheimer’s Platform Foundation’s prestigious Citizen Scientist Cultivator Award for its work bridging barriers to get more Hispanic people involved in Alzheimer’s studies, which could help millions in the future. Studies show Hispanics are 1.5 times more […]
Families demand end to Medicare waiting period for early-onset Alzheimer’s patients
This article was originally published in the Washington Examiner by Elaine Mallon Jason Raubach was diagnosed at 50 years old with early-onset Alzheimer’s disease — a diagnosis that affects nearly 200,000 Americans. He received the diagnosis in 2018, completely upending life for his family. His youngest child was just a freshman in high school. “It’s like somebody grabs you by […]
Jim Taylor: What my wife’s experience with Alzheimer’s has taught me
Posted on the Chicago Tribune on June 9, 2025. After several unexplained memory slips, there came a day when my wife, Geri, didn’t recognize her own face in the mirror. That’s when we knew it was time for her to get checked out. It was 2012, and Alzheimer’s was a feared diagnosis. At the time, […]
Global Alzheimer’s Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer’s Disease
For immediate release: Contact: [email protected] Washington D.C., May 20, The Global Alzheimer’s Platform Foundation® (GAP) applauds the FDA’s clearance of the first blood test to diagnose Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer’s—a critical […]